156 related articles for article (PubMed ID: 22651685)
41. A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.
Jiang L; Yang M; Zhang X; Bao S; Ma L; Fan D; Zhou Y; Xiong D; Zhen Y
J Drug Target; 2016; 24(1):47-57. PubMed ID: 26204323
[TBL] [Abstract][Full Text] [Related]
42. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
43. Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation.
Tao HY; He SM; Zhao CY; Wang Y; Sheng WJ; Zhen YS
Int J Biol Macromol; 2023 Jan; 226():1088-1099. PubMed ID: 36435475
[TBL] [Abstract][Full Text] [Related]
44. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Zhang SH; Zhang H; He HW; Li L; Li XQ; Zhang YP; Shao RG
Cancer Chemother Pharmacol; 2013 Oct; 72(4):777-88. PubMed ID: 23975242
[TBL] [Abstract][Full Text] [Related]
45. An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.
Sheng W; Geng J; Li L; Shang Y; Jiang M; Zhen Y
Oncol Rep; 2020 Mar; 43(3):851-863. PubMed ID: 32020213
[TBL] [Abstract][Full Text] [Related]
46. Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice.
Zhen Y; Shang B; Liu X; Lin Y; Zhen Y
J Cancer Res Ther; 2016; 12(1):182-7. PubMed ID: 27072234
[TBL] [Abstract][Full Text] [Related]
47. [Lidamycin induces apoptosis of human gastric carcinoma BGC823 cells and inhibits xenograft growth in nude mice].
Zhang SH; Chen J; Jiang M; Zhen YS
Yao Xue Xue Bao; 2008 Jun; 43(6):601-4. PubMed ID: 18822962
[TBL] [Abstract][Full Text] [Related]
48. [Bioluminescence imaging evaluation of the inhibitory effect of lidamycin on lung metastasis of human fibrosarcoma in athymic mice].
Zhang SH; Zhong GS; He HW; Cheng X; Zhen YS
Yao Xue Xue Bao; 2011 Jan; 46(1):45-9. PubMed ID: 21465808
[TBL] [Abstract][Full Text] [Related]
49. Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy.
Duanmu J; Cheng J; Xu J; Booth CJ; Hu Z
Br J Cancer; 2011 Apr; 104(9):1401-9. PubMed ID: 21427724
[TBL] [Abstract][Full Text] [Related]
50. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.
Cao R; Song W; Ye C; Liu X; Li L; Li Y; Yao H; Zhou X; Li L; Shao R
Cancer Med; 2019 Feb; 8(2):643-655. PubMed ID: 30681288
[TBL] [Abstract][Full Text] [Related]
51. Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3β/β-catenin pathway.
Chen Y; Yu D; Zhang C; Shang B; He H; Chen J; Zhang H; Zhao W; Wang Z; Xu X; Zhen Y; Shao RG
Mol Carcinog; 2015 Jan; 54(1):1-8. PubMed ID: 23857500
[TBL] [Abstract][Full Text] [Related]
52. Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer.
Wang YY; Li L; Liu XJ; Miao QF; Li Y; Zhang MR; Zhen YS
J Pharm Anal; 2022 Apr; 12(2):232-242. PubMed ID: 35582405
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.
Zhen HY; He QH; Zhen YZ; Wang SL; Liu YN; Wu WH; Zhang XY; Lu AL; Shen L
Invest New Drugs; 2011 Dec; 29(6):1188-97. PubMed ID: 20596749
[TBL] [Abstract][Full Text] [Related]
55. Lidamycin inhibits the cancer cell PKC activity induced by basic fibroblast growth factor.
Zhen HY; Huang YH; Zhen YS
Yao Xue Xue Bao; 2005 Dec; 40(12):1110-5. PubMed ID: 16496675
[TBL] [Abstract][Full Text] [Related]
56. [Optimization of the preparation process for fusion protein Fv-LDP that composes lidamycin apoprotein and single-chain Fv antibody directed against type IV collagenase].
Gao RJ; Zhao CY; Li DD; Zhen YS
Yao Xue Xue Bao; 2013 Oct; 48(10):1563-9. PubMed ID: 24417083
[TBL] [Abstract][Full Text] [Related]
57. Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM.
Xin C; Ye S; Ming Y; Shenghua Z; Qingfang M; Hongxing G; Xu S; Yuanfu X; Yuan Z; Dongmei F; Juanni L; Yingdai G; Lianfang J; Rongguang S; Zhenping Z; Jianxiang W; Tao C; Chunzheng Y; Dongsheng X; Yongsu Z
Gene Ther; 2010 Oct; 17(10):1234-43. PubMed ID: 20463754
[TBL] [Abstract][Full Text] [Related]
58. Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice.
Zhen YZ; Lin YJ; Li Y; Zhen YS
Acta Pharmacol Sin; 2009 Jul; 30(7):1025-32. PubMed ID: 19575006
[TBL] [Abstract][Full Text] [Related]
59. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.
Hu Z; Rao B; Chen S; Duanmu J
BMC Cancer; 2010 May; 10():235. PubMed ID: 20504328
[TBL] [Abstract][Full Text] [Related]
60. [Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC].
Yang J; Chen SZ
Yao Xue Xue Bao; 2010 Oct; 45(10):1247-53. PubMed ID: 21348302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
